News
PennantPark Floating Rate Capital: Strong Fiscal Q4 Earnings (NYSE:PFLT)
If you're not yet familiar with the business development company industry, you'd do well to check it out, especially if…
Dividend Champion, Contender, And Challenger Highlights: Week Of December 10
This article was written byJustin Law has a Ph.D in Chemistry from Rice University and has earned the CFA Institute…
Albemarle Presents Technical Strength Amid Market Challenges (NYSE:ALB)
Albemarle Corporation (NYSE:ALB) exhibited a notable performance in Q3 2023, marked by an increase in net sales due to the…
This Week’s Fed Meeting Could Shock Market Rates Higher
This week's FOMC meeting will likely highlight the big differences between where the Fed sees interest rates in 2024 and…
Satellogic: Nice $140 Billion Market, Bad Investment (NASDAQ:SATL)
Aerospace start-ups are intriguing companies, but in many cases, the investment case for such companies tends to be rather complicated…
UTWO: Self-Unfulfilling Prophecy Of Lower Rates (NASDAQ:UTWO)
US Treasury 2 Year Note ETF (NASDAQ:UTWO) contains simply Treasuries with a 2-year maturity and a 4.875% coupon rate and…
Buy Cabaletta Bio’s Promising SLE Treatment (NASDAQ:CABA)
Cabaletta Bio (NASDAQ:CABA) is a biotechnology company still in its clinical stages and has no revenues yet. This stock exposes…
Week In Review: Abbisko Sells China Rights For CSF-1R Inhibitor To Merck In $605M Deal
Deals and Financings Shanghai Abbisko Therapeutics has sold greater China commercialization rights for pimicotinib, a small molecule CSF-1R inhibitor, to…